Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acyclovir pharmacokinetics in plasmapheresis.

P Y Chavanet1, F Bailly, C Mousson

  • 1Service des Maladies Infectieuses et Tropicales, Hopital du Bocage, Dijon, France.

Journal of Clinical Apheresis
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Hepatitis C in a psychiatric setting: A forgotten reservoir?]

L'Encephale·2020
Same author

Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).

HIV medicine·2017
Same author

Angular momentum regulation strategies for highly dynamic landing in Parkour.

Computer methods in biomechanics and biomedical engineering·2017
Same author

Pre-transplant end-stage renal disease-related immune risk profile in kidney transplant recipients predicts post-transplant infections.

Transplant infectious disease : an official journal of the Transplantation Society·2016
Same author

[Asthenia, weight loss and abdominal pain in a 64-year-old woman].

La Revue de medecine interne·2015
Same author

Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center.

Journal of thrombosis and haemostasis : JTH·2014
Same journal

Calcium and Other Electrolyte Management in Patients Undergoing Leukocytapheresis Collections: Review and Recommendations From the American Society for Apheresis Clinical Applications Committee.

Journal of clinical apheresis·2026
Same journal

The Role of Therapeutic Apheresis in the Management of Rheumatoid Arthritis A Systematic Review and Meta-Analysis.

Journal of clinical apheresis·2026
Same journal

Thrombocytapheresis as a Bridge Intervention in JAK2-Mutant Myeloproliferative Neoplasm Complicated by Acquired von Willebrand Disease: A Case Report.

Journal of clinical apheresis·2026
Same journal

Plerixafor Plus G-CSF Versus Etoposide Combined With Cyclophosphamide and G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Single Center Observational Propensity Score-Matched Cohort Study.

Journal of clinical apheresis·2026
Same journal

Beyond the Centrifuge: Is FcRn Inhibition Ready to Replace Apheresis in Treatment of Guillain-Barré Syndrome?

Journal of clinical apheresis·2026
Same journal

Correction to "Real-World Safety Data From the World Apheresis Association Registry for the Spectra Optia Apheresis System".

Journal of clinical apheresis·2026
See all related articles

High-dose acyclovir (ACV) pharmacokinetics were studied in HIV-1 patients undergoing plasmapheresis (PE). Results indicate PE does not significantly alter ACV levels, suggesting no additional ACV doses are required during PE treatment.

Area of Science:

  • Pharmacokinetics
  • Virology
  • Nephrology

Background:

  • Human immunodeficiency virus (HIV-1) infection requires effective antiviral therapies.
  • Acyclovir (ACV) is an antiviral medication.
  • Plasmapheresis (PE) is a procedure to remove plasma components.

Purpose of the Study:

  • To evaluate the impact of plasmapheresis (PE) on acyclovir (ACV) pharmacokinetics in HIV-1 infected patients.
  • To determine if supplemental ACV doses are necessary during PE treatment.

Main Methods:

  • Pharmacokinetic parameters of ACV were measured in three HIV-1 patients.
  • Measurements were taken with and without concurrent plasmapheresis (60 ml/kg).
  • Key parameters assessed included elimination half-time, volume of distribution, and total clearance.

Related Experiment Videos

Main Results:

  • Plasmapheresis (PE) did not significantly alter ACV pharmacokinetics.
  • Elimination half-time: 3 h (without PE) vs. 2.3 h (with PE).
  • Total clearance: 404 ml/min (without PE) vs. 314 ml/min (with PE).
  • PE accounted for only 2.5% of ACV elimination.

Conclusions:

  • Supplemental acyclovir (ACV) dosing is likely unnecessary for patients undergoing plasmapheresis (PE).
  • The pharmacokinetic profile of ACV remains largely unaffected by PE.
  • This finding supports current treatment protocols for HIV-1 patients requiring both therapies.